Doug Cole

Managing Partner at Flagship Pioneering

Doug Cole

Doug Cole

Managing Partner at Flagship Pioneering

Overview
Career Highlights

Flagship Pioneering
Sigilon Therapeutics, Inc.
Inzen Therapeutics

RelSci Relationships

3277

Number of Boards

35

Birthday

1960

Age

61

Relationships
RelSci Relationships are individuals Doug Cole likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

Director & Chief Executive Officer at Moderna, Inc.

Relationship likelihood: Strong

Co-Founder at Vir Biotechnology, Inc.

Relationship likelihood: Strong

Founder at Fate Therapeutics, Inc.

Relationship likelihood: Strong

Chairman of the Board, Co-Founder at Concert Pharmaceuticals, Inc.

Relationship likelihood: Strong

Professor at Harvard University

Relationship likelihood: Strong

President at Epiva Biosciences, Inc.

Relationship likelihood: Strong

Co-Founder at Torque Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Denali Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Doug Cole
Potential Connections via
Relationship Science
You
Doug Cole
Managing Partner at Flagship Pioneering
Education
MD
Class of 1986

The University of Pennsylvania is the oldest and one of the finest medical schools in the United States. Penn is rich in tradition and heritage and at the same time consistently at the forefront of new developments and innovations in medical education and research. Since its founding in 1765 the School has been a strong presence in the community and prides itself on educating the leaders of tomorrow in patient care, biomedical research, and medical education. At Penn academic excellence, as well as compassion for the patients we are privileged to serve, are stressed. Skillful compassion is truly a hallmark of the Penn learning experience. The Perelman School of Medicine at the University of Pennsylvania consistently ranks among the top five in US News and World Report’s rankings of research-oriented medical schools.

AB
Class of 1982

Founded in 1769, Dartmouth is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools—the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

Memberships
Member
Current

Alpha Omega Alpha supports many programs for medical students and physicians at our 123 chapters, and publishes a quarterly journal, The Pharos, which contains articles on nontechnical medical subjects, including history, ethics, national issues, personal essays, and poetry.

Career History
Chairman
2015 - Current

Sigilon Therapeutics, Inc. engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.

Managing Partner
2001 - Current

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Founding Chief Executive Officer
Prior - 2021
Boards & Committees
Director
Prior - 2014

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Director
Prior - 2006

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

Political Donations
$500
2002

Senator at Office of the Senator from Utah, Mitt Romney

$200
2002

Co-Founder at Empower Schools

Investments
Details Hidden

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Details Hidden

Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA.

Details Hidden

Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Doug Cole. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Doug Cole's profile does not indicate a business or promotional relationship of any kind between RelSci and Doug Cole.